Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

The FDA has recently held a slew of so-called "expert panels" that sidestep legal procedures and ethics guardrails ...

Researchers have discovered a new way to successfully collect amniotic fluid and stem cells directly during vaginal deliveries. Plus, Rush University System for Health is offering an innovative blood ...

CVS acknowledged that Zepbound has been shown to help people lose more weight than Wegovy, but that Wegovy can still help ...

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...

The University of Pennsylvania is suing three leading insulin makers and companies that negotiate drug price deals for insurance plans, accusing them of a scheme to drive up prices of a medication ...

Roche (RHHBY) plans direct-to-patient drug sales in the U.S. to avoid the influence from pharmacy benefit managers in product ...

UnitedHealth's stock is having a rough year, down 43% so far. Jim Cramer calls it a "tragedy" on many levels. The troubles ...

For many years now, the price of insulin has continued to increase, which comes at a cost for those with diabetes who truly ...

UBS Group just sliced their target for CVS Health from $71.00 to $67.00, maintaining a 'neutral' stance. Despite this cut, ...